Key Stats for Novo Nordisk Stock
- Price Change for Novo Nordisk stock: 5.2%
- $NVO Share Price as of Jan. 5: $55.11
- 52-Week High: $93.80
- $NVO Stock Price Target: $53.54
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Novo Nordisk (NVO) stock jumped over 5% on Monday after the company launched its Wegovy pill, marking the first GLP-1 weight loss medication available in pill form in the United States. The drug is now available at more than 70,000 pharmacies nationwide, including CVS and Costco.
The Danish drugmaker is pricing the pill aggressively to compete with rival Eli Lilly. Cash-paying patients can get the starting dose for just $149 per month, far below the $1,000 monthly cost of injectable GLP-1 drugs. The highest Wegovy doses are priced at $299 per month, while patients with insurance coverage can pay as little as $25 per month.
In clinical trials, the highest dose helped patients lose an average of about 17% of their body weight after 64 weeks when all patients remained on treatment. This weight loss dropped to about 14% when analyzing all patients regardless of whether they completed the full treatment period.
The pill offers a more convenient option than injections, though it comes with some requirements. Users must take it on an empty stomach, then wait 30 minutes before eating or drinking anything.
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
What the Market Is Telling Us About Novo Nordisk Stock
The strong rally in Novo Nordisk stock suggests investors see the pill launch as a significant competitive advantage. The company now has a clear head start in the oral GLP-1 market, with Eli Lilly’s competing pill not expected to receive FDA approval until later this year.
Despite the positive momentum, Novo Nordisk stock remains down more than 40% over the past year, as investors worry about increasing competition and pricing pressure in the weight-loss drug market.
The aggressive pricing strategy announced Monday shows the company is willing to compete on cost to capture market share.
Analysts estimate the oral GLP-1 market could reach $22 billion by 2030, representing about 24% of the total weight loss drug market. With more than 100 million Americans living with obesity, the addressable market remains massive even as competition intensifies.
The launch represents a turning point for Novo Nordisk stock as the company works to regain investor confidence after a challenging year.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Novo Nordisk Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
